Live
FierceBiotechAffibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejectionClinical OMICsInfluenza Drugs Could Prevent Cognitive Decline in Chronic Viral InfectionsFierceBiotechInsulet debuts latest enhancements to popular Omnipod insulin delivery systemPharmaVoiceBMS under pressure in schizophrenia; Summit/Akeso on a winning streakPromega BlogMeasuring What Matters in Metabolic Research: A Bioluminescent ToolkitBioWorldNME Digest: Q1 2026FierceBiotechChutes & Ladders—AstraZeneca adds FDA cell and gene veteranBioWorldNew York University identifies new analogues of mannose-6-phosphateBioWorldAvelos Therapeutics synthesizes new PARG inhibitorsBioWorldSimcere Zaiming Pharmaceutical discovers new MAPK inhibitorsLabiotechEight oncology deals in 2026 spotlight where industry leaders are betting bigEndpoints NewsFulcrum lays off majority of staff; Seres extends runway into 2027
Lonza News Mar 6, 2026

Lonza Completes its Transformation to a Pure-Play CDMO with Agreement to Divest Capsules & Health Ingredients - TradingView

Lonza Completes its Transformation to a Pure-Play CDMO with Agreement to Divest Capsules & Health Ingredients - TradingView

Original
Body unavailable. Use the original source.